SNCAIP Antikörper (C-Term)

Produktnummer ABIN350930

Produktdetails anti-SNCAIP Antikörper

Target: SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SNCAIP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Spezifität: Specific for Synphilin-1.

Kreuzreaktivität: Human

Kreuzreaktivität (Details): Other species not yet tested.

Aufreinigung: IgG

Immunogen: A synthetic peptide from the c-terminal region of human Synphilin 1 conjugated to an immunogenic carrier protein was used as the antigen. The antigen shares 83% identity with mouse sequence.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.

Handhabung: Avoid freeze and thaw cycles.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Haltbarkeit: 12 months

Details zu SNCAIP

Target: SNCAIP (Synuclein, alpha Interacting Protein (SNCAIP))

Andere Bezeichnung: Synphilin 1 (SNCAIP Produkte)

Synonyme: sncaip antikoerper, MGC88953 antikoerper, SNCAIP antikoerper, LOC100221074 antikoerper, SYPH1 antikoerper, Sph1 antikoerper, Syph1 antikoerper, 2810407O15Rik antikoerper, 4933427B05Rik antikoerper, BB104594 antikoerper, synuclein alpha interacting protein antikoerper, synuclein, alpha interacting protein antikoerper, synuclein, alpha interacting protein (synphilin) antikoerper, SNCAIP antikoerper, sncaip antikoerper, Sncaip antikoerper

Hintergrund: Tissue specificity: Widely expressed, with highest levels in brain, heart and placenta. Defects in SNCAIP are a cause of Parkinson disease (PD). PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. Constructs encoding portions of SNCA and SNCAIP co-transfected in mammalian cells promote cytosolic inclusions resembling the Lewy bodies of Parkinson disease. Coexpression of SNCA, SNCAIP, and PARK2 result in the formation of Lewy body-like ubiquitin-positive cytosolic inclusions. Familial mutations in PARK2 disrupt the ubiquitination of SNCAIP and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy body-associated proteins and link PARK2 and SNCA in a common pathogenic mechanism through their interaction with SNCAIP.,Neurodegeneration,Alpha-synuclein-interacting protein, SNCAIP

UniProt: Q9Y6H5